CA
LUMO

Clearstead Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Clearstead Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35
Closed – – 1312
2021
Q1 		$0 Hold
35
– – ﹤0.01% 1196
2020
Q4 		$1K Hold
35
– – ﹤0.01% 968
2020
Q3 		$0 Hold
35
– – ﹤0.01% 934
2020
Q2 		$1K Hold
35
– – ﹤0.01% 776
2020
Q1 		$0 Buy
+35
New +$489 ﹤0.01% 787

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clearstead Advisors's LUMO Position: Q2 2021 in Review

Clearstead Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2021, closing a stake of 35 shares.

Clearstead Advisors first reported a position in LUMO in Q1 2020 and held it in 5 quarters. The position peaked at $1K in Q4 2020. 40 funds tracked by Wall St. Rank hold LUMO as of Q2 2021.

  • Clearstead Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Clearstead Advisors sold 35 Lumos Pharma, Inc. Common Stock shares in Q2 2021.
  • Clearstead Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Clearstead Advisors's Lumos Pharma, Inc. Common Stock position peaked at $1K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2021.

Based on Clearstead Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.